Neena M. Patil Sells 3,800 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Jazz Pharmaceuticals Trading Down 2.3 %

JAZZ traded down $3.31 during trading on Monday, reaching $140.22. The company had a trading volume of 964,619 shares, compared to its average volume of 729,043. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.56. The firm’s 50-day simple moving average is $126.69 and its 200 day simple moving average is $119.16.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC grew its position in Jazz Pharmaceuticals by 238.6% during the 3rd quarter. Private Advisor Group LLC now owns 7,716 shares of the specialty pharmaceutical company’s stock worth $860,000 after purchasing an additional 5,437 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Jazz Pharmaceuticals by 15.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,476 shares of the specialty pharmaceutical company’s stock worth $275,000 after buying an additional 325 shares during the period. Stephens Inc. AR grew its holdings in shares of Jazz Pharmaceuticals by 16.1% during the third quarter. Stephens Inc. AR now owns 5,563 shares of the specialty pharmaceutical company’s stock valued at $620,000 after buying an additional 771 shares in the last quarter. Van ECK Associates Corp raised its position in Jazz Pharmaceuticals by 11.4% during the third quarter. Van ECK Associates Corp now owns 60,211 shares of the specialty pharmaceutical company’s stock valued at $6,691,000 after buying an additional 6,157 shares during the period. Finally, AlphaCentric Advisors LLC lifted its stake in Jazz Pharmaceuticals by 40.9% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,500 shares of the specialty pharmaceutical company’s stock worth $1,727,000 after acquiring an additional 4,500 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Barclays reiterated an “overweight” rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, Needham & Company LLC increased their price target on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $182.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.